RADIOTHERAPY MEETS IMMUNOLOGY
A clearer view of PRaG therapy. Explore the research, understand the evidence, and follow an evolving field of cancer care.
Open knowledge. Original sources. A human perspective.
01 / THE EVIDENCE
The foundational phase II report investigated whether the PRaG triplet could produce responses in previously treated metastatic cancer.
An observational comparison examined three checkpoint-inhibitor-based strategies in MSS/pMMR metastatic colorectal cancer.
This retrospective series examines feasibility in older adults, a group often underrepresented in trials.
Study types matter. Case reports, protocols and clinical results are labeled separately throughout the library.
02 / AN EVOLVING FIELD
From an initial three-part combination to new clinical questions. A chronological perspective connects each publication to the wider story.
Open the research timeline ↗A published esophageal cancer case documents both a response and serious toxicity.
A 54-patient single-arm study evaluates the PRaG triplet.
Research expands to different combinations, populations and biomarkers.
03 / PERSPECTIVES
RESEARCH EXPLAINED · 4 MIN READ
Why promising case reports matter—and why they need careful interpretation.
Read perspective ↗RESEARCH EXPLAINED · 4 MIN READ
How to navigate the growing family of PRaG research programs.
Read perspective ↗RESEARCH EXPLAINED · 4 MIN READ
What a 54-patient study can tell us—and the questions it leaves open.
Read perspective ↗SCIENCE, WITH PEOPLE AT ITS HEART
We share research with care: explaining what it shows, what remains uncertain, and why the distinction matters.